Conditions:  Colorectal Adenocarcinoma;  Colon Cancer;  Colon Adenocarcinoma;  Rectum Cancer;  Rectal Cancer;  Rectal Adenocarcinoma;  Colorectal Cancer
Interventions: Â Drug:Â Cabozantinib; Â Drug:Â Nivolumab
Sponsors:  University of Colorado, Denver;  National Cancer Institute (NCI);  Criterium, Inc.;  Bristol-Myers Squibb;  Exelixis
**RECRUITING NOW**
Interventions: Â Drug:Â Cabozantinib; Â Drug:Â Nivolumab
Sponsors:  University of Colorado, Denver;  National Cancer Institute (NCI);  Criterium, Inc.;  Bristol-Myers Squibb;  Exelixis
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
